个人简介：

于小勇，男，1969年10月18日出生，研究生学历，学士学位，主任医师职称，陕西中医药大学博士研究生指导教师。现任陕西省中医医院肾病二科主任职务，兼任中华中医药学会肾病分会常委，中国中药协会肾病中药发展研究专业专委会常委，中国医药教育协会临床肾脏病学专委会委员，中国老年医学会肾脏病学分会委员，陕西省中医药学会肾病专业委员会副主任委员，陕西省医学会肾脏病分会副主委，陕西省医师协会肾病分会常委，陕西省血液净化质量控制专家组成员（中医单位组长），陕西省中西医结合学会慢性肾脏病治疗与管理专业委员会主任委员。

学习工作经历：

1993年7月本科毕业于陕西中医药大学，在职研究生结业于2006年，先后在延安大学附属医院、陕西省中医医院工作，主要从事肾脏病中西医结合临床、教学和科研工作32年。

研究方向：

肾间质纤维化及血液净化并发症中西医结合研究。

科研课题：

（1）陕西省中医药管理局项目（SZY-KJCYC-2025-ZY-010），探讨益血降浊汤通过肠-肾轴改善CKD肠道微生态而抗肾纤维化的作用及机制，2025-01至2026-12，在研，；主持

(2)国家自然科学基金（82174366），益血降浊汤调控Nrf2/DDAH1/miR-219a-5p信号轴而抗肾间质纤维化的机制研究， 2022.01-2025.12，在研，主持

(3)陕西省中医药管理局项目（2021-GJ-LC022），基于真实世界的益血降浊复方治疗 CKD3-4 期安全性、疗效性评价研究，2021-07-2023-07，已结题，主持；

(4)西安市科学技术局项目（2019115613YX011SF044（9）） ，丹曲胶囊治疗血液透析痰瘀互结冠心病心绞痛患者的临床疗效分析：单中心、前瞻性研究，2019-10至2021-10，已结题，主持；

(5)陕西省科技厅面上项目（2017SF-298），基于TGFβ1/p38MAPK信号通路探讨益血降浊汤对肾纤维化氧化应激作用的研究，2017-01至2019-12，已结题，主持；

(6)陕西省中医药管理局项目，益气活血降浊法抗肾间质纤维化的机理研究，2015-12至2017-12，已结题，主持；

(7)陕西省中医药管理局项目，益血降浊汤在CKD4期治疗中的临床研究，2012-12至2014-12，已结题，主持；

(8)陕西省科技厅项目，维持性血液透析患者踝肱指数与钙磷代谢紊乱的相关性研究，2011-12至2013-12，已结题，主持。

发表论文：

(1) Chen DQ, Cao G, Chen H, Argyopoulos CP, Yu H, Su W, Chen L, Samuels DC,Zhuang S, Bayliss GP, Zhao S, Yu XY, Vaziri ND, Wang M, Liu D, Mao JR, Ma SX,Zhao J, Zhang Y, Shang YQ, Kang H, Ye F, Cheng XH, Li XR, Zhang L, Meng MX, Guo Y, Zhao YY. Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan. Nat Commun. 2019 Apr 1;10(1):1476. doi: 10.1038/s41467-019-09329-0. PMID: 30931940; PMCID:PMC6443780.

（2） Miao H, Liu F, Wang YN, Yu XY, Zhuang S, Guo Y, Vaziri ND, Ma SX, Su W, Shang YQ, Gao M, Zhang JH, Zhang L, Zhao YY, Cao G. Targeting Lactobacillus johnsonii to reverse chronic kidney disease. Signal Transduct Target Ther. 2024 Aug 5;9(1):195. doi: 10.1038/s41392-024-01913-1. PMID: 39098923; PMCID: PMC11298530.

（3） Wang YN, Miao H, Yu XY, Guo Y, Su W, Liu F, Cao G, Zhao YY. Oxidative stress and inflammation are mediated via aryl hydrocarbon receptor signalling in idiopathic membranous nephropathy. Free Radic Biol Med. 2023 Oct;207:89-106. doi: 10.1016/j.freeradbiomed.2023.07.014. Epub 2023 Jul 13. PMID: 37451370.

（4） Chen H, Tian X, Yu X. Editorial: Association between diabetic nephropathy and diabetic retinopathy or non-diabetic nephropathy. Front Endocrinol (Lausanne).2024 Jan 25;15:1359011. doi: 10.3389/fendo.2024.1359011. PMID: 38332890; PMCID:PMC10852059.

（5）Ma SX, Li XJ, Duan TT, Pei M, Zou L, Yu XY, Zhao YY. Moshen granule ameliorates membranous nephropathy by regulating NF-ƙB/Nrf2 pathways via aryl hydrocarbon receptor signalling. Heliyon. 2023 Sep 9;9(9):e20019. doi: 10.1016/j.heliyon.2023.e20019. PMID: 37809643; PMCID: PMC10559749.

（6）Miao H, Wang YN, Yu XY, Zou L, Guo Y, Su W, Liu F, Cao G, Zhao YY.Lactobacillus species ameliorate membranous nephropathy through inhibiting the aryl hydrocarbon receptor pathway via tryptophan-produced indole metabolites. Br J Pharmacol. 2024 Jan;181(1):162-179. doi: 10.1111/bph.16219. Epub 2023 Sep 19.PMID: 37594378.

（7）Wu XQ, Zhang DD, Wang YN, Tan YQ, Yu XY, Zhao YY. AGE/RAGE in diabetic kidney disease and ageing kidney. Free Radic Biol Med. 2021 Aug 1;171:260-271. doi:10.1016/j.freeradbiomed.2021.05.025. Epub 2021 May 18. PMID: 34019934.

（8）Yu XY, Sun Q, Zhang YM, Zou L, Zhao YY. TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis. Front Pharmacol. 2022 Mar 24;13:860588. doi:10.3389/fphar.2022.860588. PMID: 35401211; PMCID: PMC8987592.

（9）Li SS, Sun Q, Hua MR, Suo P, Chen JR, Yu XY, Zhao YY. Targeting the Wnt/β-Catenin Signaling Pathway as a Potential Therapeutic Strategy in Renal Tubulointerstitial Fibrosis. Front Pharmacol. 2021 Aug 16;12:719880. doi: 10.3389/fphar.2021.719880. PMID: 34483931; PMCID: PMC8415231.

（10）Wang Y, Yu X. Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study. Kidney Dis (Basel).2024 Jan 3;10(2):132-142. doi: 10.1159/000536039. PMID: 38659701; PMCID:PMC11037893.

（11）Liu XY, Zhang XB, Zhao YF, Qu K, Yu XY. Research Progress of Chinese Herbal Medicine Intervention in Renal Interstitial Fibrosis. Front Pharmacol. 2022 Jun 13;13:900491. doi: 10.3389/fphar.2022.900491. PMID: 35770077; PMCID: PMC9235922.

（12）Miao H, Wang YN, Su W, Zou L, Zhuang SG, Yu XY, Liu F, Zhao YY. Sirtuin 6 protects against podocyte injury by blocking the renin-angiotensin system by inhibiting the Wnt1/β-catenin pathway. Acta Pharmacol Sin. 2024 Jan;45(1):137-149. doi: 10.1038/s41401-023-01148-w. Epub 2023 Aug 28. PMID: 37640899; PMCID: PMC10770168.

（13）Chen YY, Yu XY, Chen L, Vaziri ND, Ma SC, Zhao YY. Redox signaling in aging kidney and opportunity for therapeutic intervention through natural products. Free Radic Biol Med. 2019 Sep;141:141-149. doi: 10.1016/j.freeradbiomed.2019.06.012. Epub 2019 Jun 11. PMID: 31199964.

（14）Miao H, Zhang Y, Yu X, Zou L, Zhao Y. Membranous nephropathy: Systems biology-based novel mechanism and traditional Chinese medicine therapy. Front Pharmacol. 2022 Sep 13;13:969930. doi: 10.3389/fphar.2022.969930. PMID:36176440; PMCID: PMC9513429.

（15）Wang YN, Yang CE, Zhang DD, Chen YY, Yu XY, Zhao YY, Miao H. Long non-coding RNAs: A double-edged sword in aging kidney and renal disease. Chem Biol Interact. 2021 Mar 1;337:109396. doi: 10.1016/j.cbi.2021.109396. Epub 2021 Jan 25. Erratum in: Chem Biol Interact. 2022 Jan 25;352:109749. doi:10.1016/j.cbi.2021.109749. PMID: 33508306.

（16）Shen N, Meng Q, Zhang L, Xie H, Zhao J, Xing C, Zuo L, Long G, Zhu Q, Shan C, Cai X, Yang J, Luo X, Wang J, Ye J, Wan X, Tian S, Wu Y, Lin Y, Yu X, Li Q,Liu X, Shi Z, Zhou J, Liu C, Cao Y, Wang N, Jiang X, Wu H, Hu Y, Li L, Wang Z,He J, Cao J, Wu F, Ma C, Yin X, Li Z, Wang H, Lin H. Evaluation of safety, effectiveness and treatment patterns of sodium zirconium cyclosilicate in management of hyperkalaemia in China: a real-world study protocol. BMJ Open. 2023 Mar 8;13(3):e070530. doi: 10.1136/bmjopen-2022-070530. PMID: 36889826;PMCID: PMC10008460.

（17）Wang YN, Liu HJ, Ren LL, Suo P, Zou L, Zhang YM, Yu XY, Zhao YY. Shenkang injection improves chronic kidney disease by inhibiting multiple renin-angiotensin system genes by blocking the Wnt/β-catenin signalling pathway. Front Pharmacol. 2022 Aug 17;13:964370. doi:  0.3389/fphar.2022.964370. PMID:36059935; PMCID: MC9432462.

（18）Miao H, Wu XQ, Wang YN, Chen DQ, Chen L, Vaziri ND, Zhuang S, Guo Y, Su W, Ma SX, Zhang HQ, Shang YQ, Yu XY, Zhao YL, Mao JR, Gao M, Zhang JH, Zhao J, Zhang Y, Zhang L, Zhao YY, Cao G. 1-Hydroxypyrene mediates renal fibrosis through aryl hydrocarbon receptor signalling pathway. Br J Pharmacol. 2022 Jan;179(1):103-124. doi: 10.1111/bph.15705. Epub 2021 Nov 11. PMID: 34625952.

（19）Gao XY, Liu YM, Zheng DN, Li YW, Li H, Xiong XL, Chen HY, Wang H, Yu XY, Qu K, Jin J, Lin B, He Q. Comparison of the prophylactic antithrombotic effect of indobufen and warfarin in patients with nephrotic syndrome: a randomized controlled trial. Ren Fail. 2023 Dec;45(1):2163505. doi:10.1080/0886022X.2022.2163505. PMID: 36636998; PMCID: PMC9848225.

（20）Wang YN, Feng HY, Nie X, Zhang YM, Zou L, Li X, Yu XY, Zhao YY. Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy. Front Pharmacol. 2022 May 26;13:907108. doi: 10.3389/fphar.2022.907108. PMID: 35694252; PMCID: PMC9178124.

（21）Shen N, Zhang L, Yang J, Lin Y, Liu X, Cai X, Cao J, Zhu Q, Luo X, Wan X, Wu H, Ye J, Shan C, Xie H, Wu Y, Cao Y, Wang J, Yu X, Wang H, He J, Tian S, Wu F,Jiang X, Li L, Zuo L, Wang Z, Xing C, Yin X, Zhao J, Ma C, Long G, Li Q, Hu Y, Shi Y, Lin H. Effectiveness, safety, and treatment pattern of sodium zirconium cyclosilicate in Chinese patients with hyperkalemia: interim analysis from a multicenter, prospective, real-world study (Actualize Study). Front Pharmacol. 2024 Jul 29;15:1398953. doi: 10.3389/fphar.2024.1398953. Erratum in: Front Pharmacol. 2024 Oct 01;15:1495716. doi: 10.3389/fphar.2024.1495716. PMID: 39135788; PMCID: PMC11317418.

（22）Wang YN, Yang CE, Zhang DD, Chen YY, Yu XY, Zhao YY, Miao H. Corrigendum to "Long non-coding RNAs: A double-edged sword in aging kidney and renal disease"[Chem. Biol. Interact. 337 (2021) 109396]. Chem Biol Interact. 2022 Jan 25;352:109749. doi: 10.1016/j.cbi.2021.109749. Epub 2021 Nov 19. Erratum for: Chem Biol Interact. 2021 Mar 1;337:109396. doi: 10.1016/j.cbi.2021.109396. PMID:34802704.

（23）He P, Yu X, Zha Y, Liu J, Wang H, Huang C, Sun S, He L. Microhematuria Enhances the Risks of Relapse and Renal Progression in Primary Membranous Nephropathy. Front Med (Lausanne). 2021 Dec 9;8:704830. doi: 10.3389/fmed.2021.704830. PMID: 34957132; PMCID: PMC8695761.

（24）Wang YT, Zhang RQ, Wang SF, Li XC, Zhang N, Zhao YF, Wang Y, Yu XY, Qu K. A systematic review and meta-analysis of integrated traditional Chinese medicine and Western medicine in treating glomerulosclerosis. Medicine (Baltimore). 2021 Feb 19;100(7):e24799. doi: 10.1097/MD.0000000000024799. PMID: 33607841; PMCID:PMC7899861.

（25）Miao H, Cao G, Wu XQ, Chen YY, Chen DQ, Chen L, Vaziri ND, Feng YL, Su W, Gao Y, Zhuang S, Yu XY, Zhang L, Guo Y, Zhao YY. Identification of endogenous 1-aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation. Br J Pharmacol. 2020 Aug;177(15):3415-3435. doi: 10.1111/bph.15062. Epub 2020 May 28. PMID: 32219844; PMCID: PMC7348091.

（26）Shen N, Zhang L, Yang J, Lin Y, Liu X, Cai X, Cao J, Zhu Q, Luo X, Wan X, Wu H, Ye J, Shan C, Xie H, Wu Y, Cao Y, Wang J, Yu X, Wang H, He J, Tian S, Wu F, Jiang X, Li L, Zuo L, Wang Z, Xing C, Yin X, Zhao J, Ma C, Long G, Li Q, Hu Y, Shi Y, Lin HL. Corrigendum: Effectiveness, safety, and treatment pattern of sodium zirconium cyclosilicate in Chinese patients with hyperkalemia: interim analysis from a multicenter, prospective, real-world study (Actualize Study).Front Pharmacol. 2024 Oct 1;15:1495716. doi: 10.3389/fphar.2024.1495716. Erratum for: Front Pharmacol. 2024 Jul 29;15:1398953. doi: 10.3389/fphar.2024.1398953. PMID: 39411065; PMCID: PMC11474006.

（27）Feng YL, Chen H, Chen DQ, Vaziri ND, Su W, Ma SX, Shang YQ, Mao JR, Yu XY, Zhang L, Guo Y, Zhao YY. Activated NF-κB/Nrf2 and Wnt/β-catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria. Biochim Biophys Acta Mol Basis Dis. 2019 Sep 1;1865(9):2317-2332. doi: 10.1016/j.bbadis.2019.05.010. Epub 2019 May 16. PMID: 31102786.

著作教材：

(1)“十三五”规划教材《中医临床思维》第2版，人民卫生出版社，2021，副主编；

(2) 《陕西省腹膜透析质量控制标准》，陕西科技出版社，2022，副主编；

（3）《中国医学非药物疗法》，中国医药科技出版社，2024，常务编委；

（4）《现代中医肾脏病学》，中国医药科技出版社，2023，编委；

（5）《陕西省医疗质量控制工作手册（血液净化学分册）》，陕西科学技术出版社，编委。

授权专利：

谷林，于小勇，程小红；一种用于血液透析水处理系统中溶盐桶内的支架，2010 年 6 月 2 日，中国，ZL2018 2 0859441.0；

获奖情况：

于小勇（4/5）,程小红主任医师益肾散结法治疗肾纤维化机制及应用研，陕西省人民政府，陕西省科学技术进步奖，三等奖，2021年；

联系方式：

gub70725@126.com